Repligen Corporation $RGEN Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lowered its position in shares of Repligen Corporation (NASDAQ:RGEN) by 93.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,625 shares of the biotechnology company’s stock after selling 49,979 shares during the quarter. Intech Investment Management LLC’s holdings in Repligen were worth $594,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bayforest Capital Ltd purchased a new position in shares of Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen during the 4th quarter valued at about $33,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the 3rd quarter valued at about $29,000. Farther Finance Advisors LLC raised its stake in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of Repligen during the 3rd quarter valued at about $65,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of Repligen stock opened at $130.13 on Wednesday. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The business has a 50-day moving average price of $119.28 and a 200 day moving average price of $138.32. The firm has a market cap of $7.34 billion, a PE ratio of 144.59, a P/E/G ratio of 2.42 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the business earned $0.39 EPS. Repligen’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RGEN shares. HC Wainwright lifted their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. HSBC reduced their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Finally, Roth Mkm started coverage on Repligen in a research note on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.